The exclusive event, hosted by RedChip Companies, will feature Simon Morriss, CEO of Genetic Technologies, who will share insight into the Company's portfolio of genomics-based tests targeting health, wellness and serious disease, including the geneType multi-risk test. Scaling existing sales channels - amplifying existing sales channels for enhanced market penetration and share. Aggressive marketing - harnessing our digital initiative to swiftly tap into the burgeoning direct-toconsumer market. Expanding t ...

CHARLOTTE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, today announces the start of testing operations in the United States for its revolutionary geneType™ genetic risk assessment product series. Stemming from its significant contributions to the Human Genome Project nearly 20 years ago, GTG pioneered and patented the burgeoning area of genetic testing known ...

SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition. Bipolar disorder is a mental health condition that can cause extreme and unusual shifts in mood, energy, behavior and activity, ranging from highs (mania) to ...

Inspirational Speakers and Insightful Panels Co-hosted by the esteemed Dr. Kristi Funk and the dynamic Krystal Barter, the event featured a series of enlightening panels. Dr. Funk, Angelina Jolie's Breast Surgeon, and Krystal Barter, along with an impressive lineup of speakers including Dr. Carolynn Young, Andrea Hans, Allyn Rose Oertel, and Matthew Zachary, provided invaluable insights into the critical role of genomics in women's health. Key Sessions Included: Unpacking the Gender Health Gap: The Vital Ro ...

MELBOURNE, Australia, April 30, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and Quarterly business update for the quarter ending 30 March 2024 (Q3 FY24). Key highlights: Cash Receipts totalling A$1.8m for the quarter ending March 2024.Launched targeted digital strategy for geneType CIT Sales in the United States, driving the highe ...

MELBOURNE, Australia, April 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE, "Company", "GTG", or "Genetic Technologies")), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announces the closing of its previously announced registered offering for the purchase and sale of 1,000,000 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each representing thirty (30) ordinary shares of the Company, at ...

MELBOURNE, Australia, April 19, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE, ", Company", , ", GTG", , or ", Genetic Technologies", )), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of 1,000,000 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each representing thirty (30) ordin ...

MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has established a precision oncology division and announced its highly anticipated portfolio of new diagnostic tests under its geneType precision oncology brand. The proprietary-developed tests will provide invaluable information to medical oncologists, helping det ...

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the company's latest milestones along with our clinical adoption of the Company's groundbreaking geneType Risk Assessment Tests routinely across 12 states in the United States and nationally in Australia. The geneType team has achieved clinical proof of concept in key markets in ...

MELBOURNE, Australia, April 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the company is establishing a clinical implementation study with breast imaging centers across New York, Miami and Houston. The initiative will pilot the integration of the geneType into breast imaging centers, assisting in the streamlining of care that is currently somewhat f ...